Your browser doesn't support javascript.
loading
A Digital Protein Microarray for COVID-19 Cytokine Storm Monitoring
Yujing Song; Yuxuan Ye; Shiuan-Haur Su; Andrew Stephens; Tao Cai; Meng-Ting Chung; Meilan Han; Michael W. Newstead; David Frame; Benjamin H. Singer; Katsuo Kurabayashi.
Affiliation
  • Yujing Song; University of Michigan
  • Yuxuan Ye; University of Michigan
  • Shiuan-Haur Su; University of Michigan
  • Andrew Stephens; University of Michigan
  • Tao Cai; University of Michigan
  • Meng-Ting Chung; University of Michigan
  • Meilan Han; University of Michigan
  • Michael W. Newstead; University of Michigan
  • David Frame; University of Michigan
  • Benjamin H. Singer; University of Michigan
  • Katsuo Kurabayashi; University of Michigan
Preprint in En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20131870
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
Despite widespread concern for cytokine storms leading to severe morbidity in COVID-19, rapid cytokine assays are not routinely available for monitoring critically ill patients. We report the clinical application of a machine learning-based digital protein microarray platform for rapid multiplex quantification of cytokines from critically ill COVID-19 patients admitted to the intensive care unit (ICU) at the University of Michigan Hospital. The platform comprises two low-cost modules (i) a semi-automated fluidic dispensing/mixing module that can be operated inside a biosafety cabinet to minimize the exposure of technician to the virus infection and (ii) a 12-12-15 inch compact fluorescence optical scanner for the potential near-bedside readout. The platform enabled daily cytokine analysis in clinical practice with high sensitivity (<0.4pg/mL), inter-assay repeatability ([~]10% CV), and near-real-time operation with a 10min assay incubation. A cytokine profiling test with the platform allowed us to observe clear interleukin -6 (IL-6) elevations after receiving tocilizumab (IL-6 inhibitor) while significant cytokine profile variability exists across all critically ill COVID-19 patients and to discover a weak correlation between IL-6 to clinical biomarkers, such as Ferritin and CRP. Our data revealed large subject-to-subject variability in a patients response to anti-inflammatory treatment for COVID-19, reaffirming the need for a personalized strategy guided by rapid cytokine assays.
License
cc_no
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Prognostic_studies Language: En Year: 2020 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Prognostic_studies Language: En Year: 2020 Document type: Preprint